Home › Funds › DIADEMA PARTNERS LP › FDMT
DIADEMA PARTNERS LP position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
DIADEMA PARTNERS LP reported holding 571,107 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$7.6M, representing 1.65% of its reported portfolio and ranking #20 among its reported holdings. DIADEMA PARTNERS LP first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DIADEMA PARTNERS LP's FDMT position evolved
DIADEMA PARTNERS LP first disclosed a stake in FDMT in Q2 2026 at 571,107 shares (US$7.6M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 571.11K | $7.60M | New |
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $67.16M · Q2 2026
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- BVF INC/IL 2.88M sh · $38.29M · Q2 2026
- Trails Edge Capital Partners, LP 2.23M sh · $29.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.00M sh · $26.60M · Q2 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $12.65M · Q2 2026
- Parkman Healthcare Partners LLC 948.18K sh · $12.61M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 507.80K sh · $6.75M · Q2 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
More on DIADEMA PARTNERS LP
FAQ
How long has DIADEMA PARTNERS LP held FDMT?
DIADEMA PARTNERS LP has disclosed FDMT holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is DIADEMA PARTNERS LP's current position in FDMT?
As of Q2 2026, DIADEMA PARTNERS LP holds 571.11K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $7.60M, representing 1.65% of its reported portfolio and ranking #20.
Has DIADEMA PARTNERS LP been buying or selling FDMT?
In the latest 13F filing (Q2 2026), DIADEMA PARTNERS LP newly opened its position in FDMT.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.